Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Amyloid-β—Turning Neurogenesis Into Neurogenocide?
22 May 2009. The oldest and the youngest people are often the most vulnerable to disease. The same might be true for cells. Alzheimer disease (AD) primarily attacks those aged 65 and older, robbing them of their 65-year-old neurons—and their memories. But immature neurons might also be at risk in AD, according to a paper in this week’s Journal of Neuroscience. Ping He and senior author Yong Shen, both at Sun Health Research Institute, Sun City, Arizona, report that brain neuronal progenitors isolated from Alzheimer patients have trouble making new neurons. “We found that proliferation is fine but progenitor cells isolated from AD brain cannot differentiate into neurons,” Shen told ARF. The researchers traced the problem to amyloid-β (Aβ), which seems to block cellular signals that are essential for neurogenesis. “It is not only that neurons are degenerating in AD, but neural progenitors are suffering too,” said Shen.

Neurogenesis in the adult human brain is extremely limited. Nonetheless, recent evidence suggests that adult-born neurons can significantly contribute to function, playing roles in memory formation (see ARF related news story on Trouche et al., 2009) and even in the action of some anti-depressants (see ARF related news story). Some researchers hope that neurogenesis, either natural or from transplanted stem cells, might one day offer a way to treat neurodegenerative diseases such as AD and Parkinson’s. But Shen’s work suggests that might not be so straightforward. “There may be a pathological environment in the Alzheimer’s brain that is not suitable for stem cells. What’s more, signal transduction pathways are interrupted, and that’s not good either,” he told ARF.

Shen and He identified the neurogenesis problem when studying precursor cells from AD and age-matched healthy control brains. From the cerebral cortex they isolated glial precursor cells (GPCs), which can give rise to the three major cell types of the brain—neurons, glia, and oligodendrocytes. The researchers found that when grown in culture, GPCs from AD autopsy tissue made significantly fewer neurons than the same cells isolated from healthy tissue. GPCs and their progeny also made more Aβ40/42 than control cells, suggesting that the peptide might somehow prevent progenitors from forming neurons. To test this idea, He incubated GPCs from healthy brain with aggregates of Aβ (the peptide was incubated overnight). The treatment induced apoptosis, or programmed cell death, in cells that began to express neuron or oligodendrocyte markers, suggesting that Aβ is toxic to these fledgling cell types. In contrast, the peptide seemed to have no effect on cells differentiating toward glia. “That may help explain why there is gliosis, or activated glial cells, in the AD brain,” said Shen.

The progeny of GPC cells isolated from AD brain also had reduced expression of proneuronal genes, such as neurogenin 2 (Ngn2) and neurogenic differentiation factor 1, suggesting that pro-neuronal signals are suppressed in those cells. Since Wnt/β-catenin signaling is a major driving force in adult neurogenesis (see ARF related news story on Lie et al., 2005), He looked to see if this pathway is perturbed in progenitors from AD brain. He found that levels of Wnt and its receptor Frizzled appeared normal, but that the dynamics of β-catenin, a major downstream transcription factor, were far from it. The level of active β-catenin was significantly lower in GPCs from AD brain (and their progeny) compared to cells from normal healthy brains. In contrast, levels of inactive phosphorylated β-catenin, and its kinase, GSK-3β, were much higher than in control cells. Transfecting AD GPCs with β-catenin restored proneuronal gene expression, while silencing β-catenin in normal healthy GPCs had the opposite effect, confirming the pivotal role played by this transcription factor. Furthermore, by treating GPCs from healthy controls with Aβ aggregates, He was able to evoke an AD GPC-type expression profile, with elevated GSK-3β and phosphorylation of β-catenin, again suggesting that the peptide is bad news for neuronal differentiation. The authors also found that neurogenesis from GPCs is perturbed in APP23 transgenic mice, which overexpress Aβ, and that β-catenin signaling is attenuated in mouse progenitors as in GPCs from human AD brain. All told, the results suggest that the Aβ in the AD brain may create a noxious environment for adult neurogenesis.

This is not the first time AD has been linked to neurogenesis. Notch signaling, which requires the same presenilin that processes Aβ precursor protein (APP), helps drive adult neurogenesis (see ARF related news story on Breunig et al., 2007). Presenilin mutations may suppress it (see ARF related news story on Wen et al., 2004) even when driven by environmental enrichment (see ARF related news story), a known promoter of neurogenesis in mammals. The results also tie in with previous findings showing that mutant forms of presenilin destabilize β-catenin (see ARF related news story) and that APP signaling can suppress neurogenesis (see ARF related news story on Ma et al., 2008) .

Whether any of these APP/PS effects are solely due to production of Aβ is unclear, said Shen. He plans to study signal transduction in neural progenitors to see how it relates to APP signaling and whether tweaking various signaling pathways might help improve adult neurogenesis. In this regard, some advances have been made with embryonic stem cells. Small molecules that activate GSK-3β have been shown to activate neurogenesis, for example (see ARF related news story), and in the May 17 Nature Neuroscience online, researchers led by Freda Miller at the Hospital for Sick Children, Toronto, Canada, report on two factors that regulate neurogenesis in mouse embryonic cortical precursors. First author Andree Gauthier-Fisher and colleagues found that knocking down Lfc, a guanine nucleotide exchange factor, blocks neurogenesis, while knocking down the Lfc negative regulator Tctex-1, on the contrary boosts neurogenesis. Unlike Aβ, which seems to act on the differentiation phase of neurogenesis, Lfc seems to work on the proliferative phase, helping to orient the mitotic spindles that are necessary for cell division.—Tom Fagan.

References:
He P, Shen Y. Interruption of beta-catenin signaling reduces neurogenesis in Alzheimer’s disease. J. Neurosci. 2009 May 20; 29:6545-6557. Abstract

Gauthier-Fisher A, Lin DC, Greeve M, Kaplan DR, Rottapel R, Miller FD. Lfc and Tctex-1 regulate the genesis of neurons from cortical precursor cells. Nature Neuruscoience. 2009 May 17 online. Abstract

 
Comments on News and Primary Papers
  Comment by:  Nibaldo Inestrosa
Submitted 26 May 2009  |  Permalink Posted 26 May 2009

In this paper, He and Shen report that the renewal capacity of glial progenitor cells (GPCs) isolated from the superior temporal cortex of Alzheimer disease (AD) patients is reduced compared to that of cells from healthy controls and that this reduced neurogenesis capacity correlates with an increased GSK-3β activity and an increased phosphorylation of β-catenin. They also found that treating GPCs from healthy controls with aggregates of Aβ led to increased β-catenin phosphorylation and reduced neurogenesis. These findings suggest that Aβ-induced interruption of Wnt signaling contributes to the impairment of neurogenesis in AD patients.

Early in 2000, we proposed that a loss of the Wnt signaling was triggered by Aβ in AD (2). Later on we, and others, confirmed that Aβ induces an impairment of Wnt signaling function, indicating that a sustained loss of this pathway occurs during Aβ neurodegeneration (3). The reduction in neurogenesis in GPCs is accompanied by a decrease in the Wnt signaling function (1). This is entirely consistent with our studies, which indicate that a...  Read more


  Comment by:  Agata Copani
Submitted 28 May 2009  |  Permalink Posted 28 May 2009

This paper by He and Shen is of great interest for several reasons. The first is that the authors address the link between neurogenesis and Alzheimer disease (AD) by studying the cell fate of neural progenitors isolated from AD autopsy specimens. The second is that this study, unlike many others, is not focused on a specialized “neurogenic niche” of the adult brain but rather the cerebral cortex. This brings me to a third reason: the attention to the role of Wnt/β-catenin signaling in the fate specification of cortical multipotent progenitor cells. Wnt/β-catenin signaling is known to promote cell fate specification in the developing cortex (1), and it is also known to be impaired in AD (2,3).

He and Shen report that glial precursor cells (GPCs) isolated from AD cortices exhibit reduced differentiation toward neurons compared with GPCs from healthy controls. This phenotype is causally related to an increased GSK-3β activity with ensuing phosphorylation of β-catenin (i.e., β-catenin degradation). It is very nice that the authors demonstrate that in GPCs from APP23 transgenic...  Read more


  Comment by:  Michael Kahn, Agnes Lukaszewicz
Submitted 4 June 2009  |  Permalink Posted 4 June 2009

Editor's note: This comment contains a diagram which is also linked below in the text.

Alzheimer disease is principally characterized by a gradual and hierarchical decline in cognition, an impairment that correlates with accumulation of amyloid plaques and neurodegeneration in regions of the brain involved in higher cognitive function, such as the frontal cortex. The hippocampus represents a structure where neuroplasticity is maintained throughout life and is believed to be impaired in AD. This plasticity plays an important role in memory and response to injury. Despite extensive investigation, a mechanistic understanding of AD pathogenesis on hippocampal plasticity remains unclear. Unknown is whether hippocampal impairment is driven by cell-autonomous or non-cell autonomous mechanisms (or both). A negative correlation has been established between plaque formation and/or microglia-mediated neuroinflammation and hippocampal neurogenesis. Additionally, we have previously demonstrated that...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad